FIELD: biotechnologies.
SUBSTANCE: two antibodies against IL-21 of a human being are presented. The first antibody includes a variable region of a heavy chain, which includes SEQ ID NO: 31, 33 and 35, and a variable region of a light chain, which includes SEQ ID NO: 39, 41 and 43. The second antibody includes a variable region of heavy chain, which includes SEQ ID NO: 47, 49 and 51, and variable region of light chain, which includes SEQ ID NO: 55, 57 and 59. Besides, the invention describes hybridomes producing the first and the second antibodies against IL-21 of a human being and deposited in the collection of cultures "American Type Culture Collection" and have numbers "ATCC Patent Deposit Designation PTA-8790" and "ATCC Patent Deposit Designation PTA-8786" respectively.
EFFECT: invention allows obtaining antibodies to IL-21 of a human being.
48 cl, 4 dwg, 16 tbl, 23 ex
Title | Year | Author | Number |
---|---|---|---|
IL-17A LINKING AGENT AND METHODS FOR USE THEREOF | 2014 |
|
RU2682046C1 |
NOVEL ANTI-IL13 ANTIBODIES AND USE THEREOF | 2004 |
|
RU2487887C2 |
INTERLEUKIN-13-BINDING PROTEINS | 2012 |
|
RU2605327C2 |
ANTIBODIES RAISED AGAINST α-INTERFERON | 2002 |
|
RU2314317C2 |
INTERLEUKIN-13-BINDING PROTEINS | 2016 |
|
RU2650767C2 |
INTERFERON ALPHA 1 RECEPTOR ANTIBODIES AND USE THEREOF | 2005 |
|
RU2600884C2 |
IMMUNOGLOBULINS | 2005 |
|
RU2404192C2 |
INTERLEUKIN-13 BINDING PROTEINS | 2007 |
|
RU2472807C2 |
IL2 ANTIBODIES | 2006 |
|
RU2425054C2 |
MONOCLONAL ANTIBODY DIRECTED AGAINST GNA33 PEPTIDE AND ITS APPLICATION | 2002 |
|
RU2355704C2 |
Authors
Dates
2014-01-20—Published
2008-12-08—Filed